Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients
Key facts
- Who runs it
- Northwestern University
- Where
- Chicago, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 19 people enrolled
- Started
- Oct 2015
- Ended
- Dec 2023
- Type of study
- Observational, 3 groups
- Treatments tested
- Influenza vaccine
- Record updated
- 16 May 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (5)Hide the full registry criteria
Who can take part
- Adults who have received either a combined kidney/stem cell transplant and have achieved chimerism or post-transplant recipients who are maintained on standard immunosuppressive therapy. Additionally, healthy controls of either gender ≥ 18 years of age will also be recruited
- Subjects must be willing and able to receive the IIV4 and provide blood samples at research visits
- Subjects must be willing and able to read, understand, and be capable of giving informed consent for prospective enrollment
Who cannot take part
- Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating. Specific conditions include but are not limited to anemia prohibitive of phlebotomy, coagulopathy or inability to receive the IIV4
- Subjects less than 18 years of age
Where in United States
- Northwestern University-Comprehensive Transplant CenterChicago, United States
About the trial
What the trial wants to find out
Influenza infection in solid organ transplant recipients is associated with increased morbidity and mortality compared to non-transplanted controls, due in part to the effects of immunosuppression which is necessary to prevent rejection of the transplanted organ. However, transplant patients are less likely to produce antibodies when vaccinated and when they do, the peak and duration of antibody responses are reduced compared to healthy controls. There are considerable differences in the magnitude of these responses, reflecting variability in individual responses to the influenza vaccine and to the immunosuppression regimen. The investigators hypothesize that chimeric kidney transplant recipients off of immunosuppression will have post vaccine immune responses that are comparable to age and gender matched healthy controls.
The 3 groups in the trial
- Transplant recipients (Chimeric)
Adults who have received a kidney/stem cell transplant and have achieved chimerism will receive the IIV4 (influenza vaccine).
Treatment: Influenza vaccine
- Transplant recipients (IS)
Adults who have received a kidney/stem cell transplant and are currently maintained on standard immunosuppressive therapy will receive the IIV4 (influenza vaccine).
Treatment: Influenza vaccine
- Controls
Healthy adults who meet inclusion and exclusion criteria will receive the IIV4 (influenza vaccine).
Treatment: Influenza vaccine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 16 May 2025